Creative Touch Permanent Makeup and Aesthetics

Carnitine palmitoyltransferase-1 (CPT-1) is the rate-limiting enzyme of mitochondrial fatty acid oxidation, embedded in the outer mitochondrial membrane and responsible for converting long-chain acyl- CoA esters into acylcarnitines – the form in which fatty acids can cross into the mitochondrial matrix for β-oxidation. Its position makes it the gatekeeper between cytosolic fat storage and mitochondrial fat burning. CPT-1 is potently inhibited by malonyl-CoA, a lipogenic intermediate produced when glucose and insulin are elevated – making it the primary molecular mechanism by which carbohydrate intake suppresses fat oxidation. Three tissue-specific isoforms exist, with CPT1B in muscle being 30–100 times more sensitive to malonyl-CoA than the liver’s CPT1A. In the skin, a 2025 study identified disrupted CPT-1 activity in psoriasis, mediated by reduced adiponectin and AMPK signalling, connecting lipid metabolism dysregulation to keratinocyte hyperproliferation through this enzyme. ^[5]

Carnitine palmitoyltransferase-1 is the enzyme at which the decision to oxidise long-chain fat is made. Embedded in the outer mitochondrial membrane, it catalyses the first and rate-limiting step of the carnitine shuttle: the transfer of the long-chain acyl group from acyl-CoA to carnitine, producing acylcarnitine and releasing free CoA back to the cytosol. Without this conversion, long-chain fatty acids of twelve carbons or more cannot cross into the mitochondrial matrix for β-oxidation. CPT-1 does not complete the oxidation of fat – it controls access to the compartment where oxidation occurs, which is a meaningful distinction: everything that regulates whether fat burns in a given cell or tissue ultimately operates through CPT-1 activity. ^[5]

The Carnitine Shuttle: Mechanism from Cytosol to Matrix

Long-chain fatty acid oxidation requires a coordinated four-component system to transport activated fatty acids across the mitochondrial membranes. ^[6]

Step 1 – Activation: Long-chain fatty acids are first activated in the cytosol by acyl-CoA synthetase ligases (ACSL), particularly ACSL1, which converts them to long-chain acyl-CoA esters (consuming one ATP). ACSL1 is physically associated with CPT-1 on the outer mitochondrial membrane, forming part of a protein complex that also includes the voltage-dependent anion channel (VDAC). This spatial clustering channels activated acyl-CoA directly toward CPT-1 rather than allowing it to diffuse freely through the cytosol. ^[4]

Step 2 – CPT-1 (rate-limiting gate): CPT-1, facing the cytoplasm from the outer mitochondrial membrane, transfers the acyl group from CoA to carnitine, producing long-chain acylcarnitine and releasing free CoA. The free CoA release is metabolically significant: it is the CoA that becomes available for the next activation cycle. The acylcarnitine product is now in the mitochondrial intermembrane space. ^[5]

Step 3 – CACT transport: The carnitine-acylcarnitine translocase (CACT), an antiport carrier in the inner mitochondrial membrane, transports acylcarnitine into the mitochondrial matrix whilst simultaneously exporting free carnitine back to the cytosol for reuse. ^[6]

Step 4 – CPT-2 (matrix reconversion): On the matrix side of the inner membrane, carnitine palmitoyltransferase-2 (CPT-2) reverses the CPT-1 reaction: it cleaves carnitine from acylcarnitine and regenerates acyl-CoA within the matrix, where it then enters β-oxidation. The carnitine released is exported back to the cytosol via CACT to complete the cycle. ^[6]

The entire shuttle is blocked at step 2 when CPT-1 is inhibited. No matter how much activated acyl-CoA accumulates in the cytosol, if CPT-1 is inactive, long-chain fatty acids cannot enter the mitochondria and are rerouted toward esterification and triglyceride storage.

Structure: A Membrane-Embedded Regulator

CPT1A – the most studied isoform – is a 773 amino acid integral membrane protein whose crystal structure has not yet been determined; it loses catalytic activity upon solubilisation from the membrane, making structural resolution technically challenging. From biochemical and modelling studies, its architecture is understood as: a short N-terminal regulatory domain (approximately 47 amino acids) on the cytoplasmic face; two transmembrane helices (TM1 and TM2) anchoring it in the outer mitochondrial membrane; and a large C-terminal catalytic domain (residues 123–773) that contains both the active site and the malonyl-CoA binding site, facing the cytoplasm. ^[5]

The N-terminal domain (residues 1–42) is not merely structural – it is the primary modulator of malonyl-CoA sensitivity. It exists in two conformational states: an Nα (inhibitory) state, in which it interacts with the malonyl-CoA binding site in the C-terminus and increases the enzyme’s sensitivity to inhibition; and an Nβ (non-inhibitory) state, in which this interaction is absent. The membrane environment matters here: membrane curvature and lipid composition influence which N-terminal state predominates, which in turn affects how readily malonyl-CoA can suppress activity. This provides a mechanism by which membrane lipid composition – itself influenced by dietary fat quality and metabolic state – can modulate CPT-1’s regulatory sensitivity at a structural level. ^[2]

CPT1A assembles in the membrane as trimers, which can further associate into hexamers. This oligomerisation state is also linked to malonyl-CoA sensitivity, though the functional implications of the oligomeric form are not yet fully characterised. The ACSL1/VDAC/CPT1A complex on the outer membrane represents a channelling architecture that coordinates fatty acid activation and transport as a functional unit rather than through independent diffusion steps. ^[4]

Three Isoforms: Different Gates for Different Tissues

Three CPT1 isoforms are expressed with distinct tissue distributions and functional properties: ^[2]

The isoform sensitivity difference between CPT1A and CPT1B is physiologically consequential. At the malonyl-CoA concentrations found in both liver and muscle (~1–5 μM in rats, but approximately 10-fold lower in human muscle), the liver’s CPT1A retains significant activity whilst the muscle’s CPT1B is substantially inhibited. This allows the liver to continue some degree of fatty acid handling even during the fed state, whilst skeletal muscle’s fat oxidation is more completely gated off by rising malonyl-CoA in response to carbohydrate intake and insulin elevation. ^[3]

CPT1C’s role is distinct enough to warrant separate framing. Located partly on the endoplasmic reticulum rather than exclusively on mitochondrial outer membranes, and with very low acyltransferase activity, it appears to function as a metabolic sensor – responding to malonyl-CoA and ceramide levels to influence appetite signalling in hypothalamic neurons. A rare dominant variant (P479L) causes hereditary spastic paraplegia, a phenotype that has nothing in common with CPT1A deficiency, consistent with its separate function. ^[2]

Malonyl-CoA: The Glucose Signal That Closes the Gate

Malonyl-CoA inhibits CPT-1 through allosteric binding at the C-terminal domain, with the degree of inhibition dependent on both the malonyl-CoA concentration and the N-terminal conformational state described above. The inhibition is concentration-dependent and reversible – when malonyl-CoA falls, CPT-1 activity recovers. ^[5]

Malonyl-CoA is produced from cytosolic acetyl-CoA by acetyl-CoA carboxylase (ACC), specifically the ACC2 isoform on the outer mitochondrial membrane in heart and skeletal muscle. Its concentration tracks closely with the cell’s glucose/insulin state: rising glucose → rising insulin → rising ACC activity → rising malonyl-CoA → CPT-1 inhibition → fat oxidation suppressed. Conversely, fasting or carbohydrate restriction → insulin falls → AMPK activated (or ACC less active) → malonyl-CoA falls → CPT-1 de-inhibited → fat oxidation restored.

This is the molecular mechanism of the Randle Cycle’s glucose-suppresses-fat direction, and it is the reason why dietary carbohydrate intake and fat oxidation are inversely linked at the enzyme level – not through any direct competition for the same active site, but through a signalling molecule whose concentration is an accurate real-time gauge of glycaemic status. Malonyl-CoA receives its own entry in this knowledge base; this section addresses its interaction with CPT-1 specifically.

A biochemically interesting competitor for the malonyl-CoA binding site is butyryl-CoA, the activated form of butyrate (a short-chain fatty acid produced by gut microbiome fermentation of dietary fibre). Butyryl-CoA competes at the same site (His473) and can displace malonyl-CoA’s inhibition, partially restoring CPT1A activity. This is one mechanism by which butyrate from gut fermentation may support fatty acid oxidation and immune cell (specifically regulatory T cell) function – a mechanistic connection between gut microbiome health and mitochondrial fatty acid handling. ^[5]

Regulation Beyond Malonyl-CoA

The malonyl-CoA/ACC axis is the primary acute regulatory mechanism, but CPT-1 expression and activity are subject to several longer-term controls: ^[5]

PPARα is the primary transcriptional activator of CPT1A in the liver and heart. Fatty acids themselves are PPARα ligands, creating a feedforward loop: rising fatty acid availability activates PPARα, which upregulates CPT1A transcription, which increases fatty acid oxidation capacity. Starvation and high-fat diets both engage this axis. PPARα agonists (fibrate drugs) leverage this pathway for triglyceride lowering.

Insulin acts on CPT1A in two directions: it reduces CPT1A transcription and simultaneously increases the enzyme’s sensitivity to malonyl-CoA inhibition. These two effects are redundant – both ensure that fat oxidation is suppressed in the fed, insulin-replete state. Insulin resistance, by reducing insulin’s transcriptional and sensitivity effects, theoretically could preserve some CPT1A activity – but this is offset in practice by the constitutively elevated malonyl-CoA and ACC activity that accompanies chronic insulin resistance. ^[5]

Adiponectin (ADIPOQ) activates AMPK, which phosphorylates and inactivates ACC, reducing malonyl-CoA production and de-inhibiting CPT-1. Adiponectin is inversely correlated with adiposity – it is typically low in obesity and metabolic syndrome. Falling adiponectin → reduced AMPK activation → higher malonyl-CoA → CPT-1 more inhibited. This is one mechanism linking excess adiposity to reduced fat oxidation capacity independently of dietary carbohydrate intake. ^[8]

Exercise increases skeletal muscle CPT1B activity primarily through mitochondrial biogenesis – aerobically trained individuals have approximately 70% higher CPT-1 activity than sedentary individuals in vastus lateralis muscle biopsies, correlating with citrate synthase activity and VO₂max. This is a mitochondrial content effect, not a change in intrinsic enzyme activity or malonyl-CoA sensitivity per se: more mitochondria means more CPT-1 enzyme molecules available. AMPK activation during exercise also acutely reduces malonyl-CoA via ACC inhibition, providing immediate de-inhibition during the exercise bout itself. ^[1]

CPT-1, Lipotoxicity, and Insulin Resistance

When CPT-1 is inhibited – by elevated malonyl-CoA in the glucose/insulin-saturated state – long-chain fatty acids cannot enter the mitochondria for oxidation and are rerouted toward esterification pathways in the cytosol. When both glucose and fat are simultaneously elevated (the “metabolic impasse” described in the Randle Cycle entity), fatty acids accumulate as diacylglycerol (DAG) and ceramides – lipid intermediates that directly impair insulin signalling by activating protein kinase C (PKC), which phosphorylates IRS-1 at serine residues rather than tyrosine, blocking the insulin receptor substrate cascade. This is the lipotoxicity mechanism of insulin resistance. ^[3]

Direct experimental confirmation comes from a 2016 study published in the American Journal of Physiology (Aguer et al.), in which mice with skeletal muscle-specific expression of a malonyl-CoA-insensitive CPT1 mutant (CPT1mt) were protected against high-fat/high-sucrose diet-induced insulin resistance – despite equivalent body weight gain and adiposity. These mice showed preserved muscle insulin signalling, increased muscle glycogen, and upregulated glucose metabolism genes compared with wild-type controls fed the same diet. The critical variable was not how much fat the mice ate, but whether that fat could enter the mitochondria for clean oxidation rather than accumulating as lipotoxic intermediates. ^[7]

Clinical Pearl This study is a direct experimental test of the mechanistic logic: releasing CPT-1 from malonyl-CoA inhibition protects against insulin resistance even in a dietary context that would normally induce it. The implication is that restoring the cell’s ability to oxidise fat – through whatever means reduces malonyl-CoA (carbohydrate reduction, AMPK activation via exercise or dietary strategies) – is mechanistically protective against lipotoxicity, not simply beneficial through weight or calorie effects.

CPT-1 in Skin: Psoriasis, Keratinocytes, and the AMPK Axis

CPT-1’s relevance to skin biology extends beyond the metabolic contexts discussed above. A 2025 study by Xing and colleagues (Scientific Reports) identified the adiponectin/AMPK/CPT-1 axis as a regulatory mechanism in psoriatic keratinocyte hyperproliferation, connecting systemic metabolic disruption to one of psoriasis’s defining pathological features. ^[8]

The study found that adiponectin (ADIPOQ) is significantly downregulated in psoriatic skin lesions and psoriatic dermal mesenchymal stem cells (MSCs). ADIPOQ overexpression in psoriatic MSCs activated AMPK phosphorylation and measurably increased CPT-1 enzyme activity, increasing fatty acid oxidation capacity. When psoriatic MSCs with restored ADIPOQ were co-cultured with normal human epidermal keratinocytes (NHEKs), keratinocyte proliferation was inhibited – linking CPT-1’s metabolic function in MSCs to the paracrine signals that govern keratinocyte behaviour. In an imiquimod-induced psoriasis mouse model, systemic ADIPOQ administration improved epidermal thickening, reduced IL-17A, TNF-α, IL-23, and IL-6 expression, and was accompanied by upregulation of AMPK and CPT-1 in skin tissue. ^[8]

The mechanistic interpretation: reduced adiponectin in psoriasis → insufficient AMPK activation → ACC remains active → malonyl-CoA elevated → CPT-1 inhibited → impaired fatty acid oxidation in dermal MSCs → altered paracrine signalling → keratinocyte hyperproliferation. Restoring the adiponectin/AMPK/CPT-1 axis corrected the downstream inflammatory and proliferative abnormalities.

The study’s authors acknowledge limitations: it is a mouse model study with in vitro coculture components; direct clinical evidence in human psoriasis patients is not yet available, and the precise paracrine mediators linking MSC lipid metabolism to keratinocyte behaviour have not been fully characterised. The finding should be treated as mechanistically grounded and directionally supported rather than clinically established. The psoriasis/metabolic syndrome comorbidity it addresses – well-documented epidemiologically – provides a plausible biological substrate for the mechanism described.